Moderna Stock Pops 14% on Early Hantavirus Vaccine Work
TL;DR
Moderna’s shares jumped about 14% after news of early hantavirus vaccine research with the U.S. Army and Korea University, though executives say the work is in its infancy and not close to a vaccine. Experts note funding has been limited because hantavirus outbreaks are rare, suggesting a vaccine could be years or even a decade away. Wall Street shows a Hold consensus on MRNA with a $41.75 target implying potential downside, so the stock move reflects long‑term research interest rather than near‑term product prospects.
- Moderna (MRNA) Stock Surges 14% on Hantavirus Vaccine. Here’s What Investors Should Know TipRanks
- Moderna flags work on hantavirus vaccines before cruise outbreak The Boston Globe
- Scientists are working on a hantavirus vaccine — but it’s likely years away NBC News
- Opinion | The hantavirus outbreak underscores the need for mRNA vaccines The Washington Post
- How Hantavirus Made Moderna a Must-Own Stock Again Barron's
Want the full story? Read the original reporting
Read on TipRanks